S-Docs Unveils Next-Level Experience To Redefine Operational Efficiency
S-Docs, a market leader in document automation and e-signature, today announced three major upgrades to its flagship document automation solution. Set to be released in separate installments, these updates include a consolidated document creation workflow, a best-in class template editor experience, and an AI-driven document assistant.
“S-Docs is innovating to redefine productivity for our customers,” said Brian Stimpfl, Chief Executive Officer at S-Docs. “This new product evolution will dramatically streamline our users' workflows to maximize operational efficiency and elevate the customer experience.”
The first update marks the largest customer experience overhaul in S-Docs history. Anticipated for release this month, this feature empowers users to generate, view, and distribute documents from their existing work interface. “What used to require multiple steps is now one fluid operation,” said Anand Narasimhan, Chief Technology Officer at S-Docs. “This transformation will mark a major shift in our customers’ approach to document automation and reinforces our dedication to seamless customer experiences.”
In addition, S-Docs is launching an entirely new template editor in early 2024. This redesigned, intuitive interface will streamline and democratize template creation across all levels and roles within an organization. “Our aim is to simplify the document lifecycle from start to finish,” stated Anand Narasimhan. “The new editor will allow any user to construct dynamic documents that are always connected to the people, processes, and data that go into them.”
Finally, S-Docs is introducing generative AI to its products in 2024. This innovation will enable customers with a document copilot, providing dynamic content generation and document analysis capabilities. “By integrating AI, we’re enabling both end users and administrators to achieve in seconds what used to take hours,” Anand Narasimhan explained. “With integrity at the heart of S-Docs’ core values, we’re developing our AI solutions within a zero-trust security framework to put data privacy first as we pave the way for a new era in document automation.”
“These updates represent a significant milestone in S-Docs’ vision to revolutionize the way organizations create, manage, and share information,” said Brian Stimpfl.
As businesses look to stay ahead in a rapidly changing landscape, S-Docs’ product enhancements are poised to set new benchmarks for operational efficiency.
To learn more about S-Docs, please visit www.sdocs.com.
About S-Docs:
S-Docs is a document automation and e-signature solution for Salesforce. Companies of all sizes in every industry rely on S-Docs to eliminate manual work and simplify complex processes, resulting in increased productivity, enhanced customer experiences, and accelerated business success.
The company is privately held with headquarters in New York and offices in Ann Arbor. Learn more at sdocs.com and follow us on LinkedIn.
Use of the term Salesforce are the trademarks of Salesforce.com, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912664296/en/
Contact information
Dyana Quinlivan
dquinlivan@sdocs.com
(303)263-6741
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom